Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 3,370,000 shares, a decline of 8.9% from the December 31st total of 3,700,000 shares. Based on an average trading volume of 247,300 shares, the short-interest ratio is presently 13.6 days.
Krystal Biotech Stock Up 0.3 %
Krystal Biotech stock traded up $0.51 during midday trading on Wednesday, reaching $161.81. 111,822 shares of the stock traded hands, compared to its average volume of 238,980. The stock's fifty day moving average is $164.24 and its 200-day moving average is $178.69. Krystal Biotech has a 12 month low of $107.50 and a 12 month high of $219.34. The stock has a market cap of $4.65 billion, a P/E ratio of 91.41 and a beta of 0.84.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company's revenue for the quarter was up 879.9% on a year-over-year basis. During the same period last year, the company earned ($0.67) EPS. On average, equities analysts predict that Krystal Biotech will post 3.22 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of analysts have commented on the company. HC Wainwright restated a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a research report on Wednesday, December 18th. Chardan Capital restated a "buy" rating and issued a $212.00 price target on shares of Krystal Biotech in a research report on Wednesday, December 18th. Finally, Citigroup upped their price target on Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Krystal Biotech currently has a consensus rating of "Buy" and a consensus target price of $206.67.
Check Out Our Latest Research Report on Krystal Biotech
Insider Buying and Selling
In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 14.10% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Krystal Biotech
Several institutional investors have recently modified their holdings of the stock. State Street Corp lifted its stake in shares of Krystal Biotech by 9.0% in the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company's stock valued at $264,455,000 after purchasing an additional 119,936 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Krystal Biotech by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company's stock valued at $107,714,000 after purchasing an additional 11,411 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Krystal Biotech by 34.2% in the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock valued at $43,774,000 after purchasing an additional 62,178 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Krystal Biotech by 9.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company's stock valued at $43,727,000 after purchasing an additional 19,777 shares during the last quarter. Finally, Braidwell LP lifted its stake in shares of Krystal Biotech by 57.4% in the 3rd quarter. Braidwell LP now owns 168,691 shares of the company's stock valued at $30,707,000 after purchasing an additional 61,512 shares during the last quarter. 86.29% of the stock is owned by institutional investors.
About Krystal Biotech
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Further Reading
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
